GenSight Biologics: Gene therapy: retinal & CNS degenerative pathologies and mitochondrial disease. Lead, GS010, Ph 3 for Leber Hereditary Optic Neuropathy (LHON). REVERSE Ph 3 topline data announced Apr 2018, RESCUE Ph 3 72-week data reported April 2019. Third Ph 3, REFLECT, exp 2020. Filing for MAA exp Q4 2019 in EU and 2020 in US. Pipeline concomitant program, GS030: optogenetic combo drug + enhancing goggle device: non-syndromic retinitis pigmentosa. Optogenetic program and targeted disease immediately transferable to dry AMD. Platform combines mono-genetic therapy-based approach w core technology platform and proprietary Mitochondrial Targeting Sequence.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Ophthalmology
Industry
Biotechnology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Gene Therapy
Website:
Address:
74, rue du Faubourg Saint-Antoine
Paris, 75012
France

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

GenSight Biologics KOL Event New York 2019

New York, May 23, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.